Literature DB >> 15695971

Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes.

Ricardo Gomez1, Roberto Romero, Luis Medina, Jyh Kae Nien, Tinnakorn Chaiworapongsa, Mario Carstens, Rogelio González, Jimmy Espinoza, Jay D Iams, Sam Edwin, Iván Rojas.   

Abstract

OBJECTIVE: The purpose of this study was to examine the diagnostic performance of ultrasonographic measurement of the cervical length and vaginal fetal fibronectin determination in the prediction of preterm delivery in patients with preterm uterine contractions and intact membranes. STUDY
DESIGN: Ultrasound examination of the cervical length and fetal fibronectin determination in vaginal secretions were performed in 215 patients admitted with preterm uterine contractions (22-35 weeks) and cervical dilatation of </=3 cm. Outcome variables were the occurrence of preterm delivery within 48 hours, 7 days, and 14 days of admission, delivery </=32 and </=35 weeks, as well as the admission-to-delivery interval. Statistical analysis included chi-square test, receiver-operator characteristic (ROC) curve analysis, logistic regression, and survival analysis.
RESULTS: The overall prevalence of preterm delivery </=35 weeks was 20% (43/215). The prevalence of spontaneous preterm delivery within 48 hours, 7 days, and 14 days of admission, and delivery </=32 and </=35 weeks were 7.9% (17/215), 13.0% (28/215), 15.8% (34/215), 8.9% (9/101), and 15.8% (34/215), respectively. ROC curve analysis and contingency tables showed a significant relationship between the occurrence of preterm delivery and both cervical length and fetal fibronectin results ( P < .01 for each). Both tests performed comparably in the prediction of spontaneous preterm delivery. However, when fetal fibronectin results were added to those of cervical length (<30 mm), a significant improvement in the prediction of preterm delivery was achieved.
CONCLUSION: Fetal fibronectin adds prognostic information to that provided by sonographic measurement of the cervical length in patients with preterm uterine contractions and intact membranes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695971     DOI: 10.1016/j.ajog.2004.09.034

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  20 in total

1.  The clinical significance of a positive Amnisure test in women with preterm labor and intact membranes.

Authors:  Seung Mi Lee; Roberto Romero; Jeong Woo Park; Sun Min Kim; Chan-Wook Park; Steven J Korzeniewski; Tinnakorn Chaiworapongsa; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2012-04-25

Review 2.  Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data.

Authors:  Roberto Romero; Kypros Nicolaides; Agustin Conde-Agudelo; Ann Tabor; John M O'Brien; Elcin Cetingoz; Eduardo Da Fonseca; George W Creasy; Katharina Klein; Line Rode; Priya Soma-Pillay; Shalini Fusey; Cetin Cam; Zarko Alfirevic; Sonia S Hassan
Journal:  Am J Obstet Gynecol       Date:  2011-12-11       Impact factor: 8.661

Review 3.  The preterm parturition syndrome.

Authors:  R Romero; J Espinoza; J P Kusanovic; F Gotsch; S Hassan; O Erez; T Chaiworapongsa; M Mazor
Journal:  BJOG       Date:  2006-12       Impact factor: 6.531

4.  The utility of fetal fibronectin in the prediction and prevention of spontaneous preterm birth.

Authors:  Daniel G Kiefer; Anthony M Vintzileos
Journal:  Rev Obstet Gynecol       Date:  2008

5.  The utility of fetal fibronectin in asymptomatic singleton and twin pregnancies with a cervical length ≤ 10 mm.

Authors:  Noelia Zork; Moti Gulersen; Anne Mardy; Caroline Pessel; Sara Brubaker; Joy Vink; Cynthia Gyamfi-Bannerman; Cande V Ananth
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-13

6.  Ultrasonic attenuation estimation of the pregnant cervix: a preliminary report.

Authors:  B L McFarlin; T A Bigelow; Y Laybed; W D O'Brien; M L Oelze; J S Abramowicz
Journal:  Ultrasound Obstet Gynecol       Date:  2010-08       Impact factor: 7.299

7.  Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance.

Authors:  Roberto Romero; Jezid Miranda; Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Francesca Gotsch; Zhong Dong; Ahmed I Ahmed; Bo Hyun Yoon; Sonia S Hassan; Chong J Kim; Steven J Korzeniewski; Lami Yeo; Yeon Mee Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2014-09-24

8.  Critical appraisal and clinical utility of atosiban in the management of preterm labor.

Authors:  Olaleye Sanu; Ronald F Lamont
Journal:  Ther Clin Risk Manag       Date:  2010-04-26       Impact factor: 2.423

Review 9.  Vaginal progesterone vs. cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis.

Authors:  Agustin Conde-Agudelo; Roberto Romero; Kypros Nicolaides; Tinnakorn Chaiworapongsa; John M O'Brien; Elcin Cetingoz; Eduardo da Fonseca; George Creasy; Priya Soma-Pillay; Shalini Fusey; Cetin Cam; Zarko Alfirevic; Sonia S Hassan
Journal:  Am J Obstet Gynecol       Date:  2012-11-15       Impact factor: 8.661

10.  Cost-effectiveness of fibronectin testing in a triage in women with threatened preterm labor: alleviation of pregnancy outcome by suspending tocolysis in early labor (APOSTEL-I trial).

Authors:  Jolande Y Vis; Femke F Wilms; Martijn A Oudijk; Martina M Porath; Hubertina C J Scheepers; Kitty W M Bloemenkamp; Annemiek C Bolte; Jérôme Cornette; Jan B Derks; Johannes J Duvekot; Jim van Eyck; Anneke Kwee; Brent C Opmeer; Maria G van Pampus; Fred K Lotgering; Sicco A Scherjon; Krystyna M Sollie; Marc E A Spaanderman; Christine Willekes; Joris A M van der Post; Ben Willem J Mol
Journal:  BMC Pregnancy Childbirth       Date:  2009-09-01       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.